Follicle Stimulating Hormone Market: Major Trends Reshaping the Future of the Industry

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Follicle Stimulating Hormone Industry Market Size Be by 2025?
There has been a consistent expansion in the market size of the follicle stimulating hormone in the past few years. The market is projected to increase from $2.03 billion in 2024 to $2.12 billion in 2025, with a compound annual growth rate (CAGR) of 4.4%. This growth during the historical period can be ascribed to factors like a rise in hormonal disorders, an increased demand for fertility treatments, the broadening of FSH indications, introduction of new FSH products in the market, and an escalating demand for safe and effective contraceptive options.

What's the Long-Term Growth Forecast for the Follicle Stimulating Hormone Market Size Through 2029?
In the coming years, the follicle stimulating hormone market is anticipated to experience robust growth. The market is forecasted to expand to ""$2.59 billion in 2029, with a compound annual growth rate (CAGR) of 5.2%. The prospective growth for the forecast period is influenced by factors such as the broadening of therapeutic applications, the increased demand for combination therapy, the rising necessity for effective contraceptive options, and the healthcare requirements of an aging population. Market growth in key areas also contributes to this expansion. The forecast period is marked by key developments such as advanced biosimilar FSH products, regulatory sanctions and market accessibility, progress in FSH production and delivery technology, and a growing requirement for effective contraceptive options.

View the full report here:
https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

What Are the Key Growth Drivers Fueling the Follicle Stimulating Hormone Market Expansion?
The continuing rise in infertility rates is predicted to spur the expansion of the follicle-stimulating hormone market. Infertility, characterized by the failure to get pregnant after a year or more of consistent, unprotected intercourse, is a condition that can impact both male and female reproductive systems. Follicle-stimulating hormone plays a crucial role in encouraging egg development in ovaries and menst*ruation regulation in women. Similarly, in men, it stimulates testicular growth and contributes to the generation of a vital protein necessary for male fertility through healthy sperm cell development. For example, the World Health Organization, a specialist agency of the United Nations based in Switzerland, stated in April 2023 that about 1 in 6 adults globally, or approximately 17.5% of all adults, were affected by infertility. Moreover, the Australian Bureau of Statistics, an independent statutory body in Australia responsible for collecting and scrutinizing data and providing evidence-based advice to the national, state, and territory administrations, noted in October 2023 that there were 300,684 recorded births in Australia in 2022, a reduction of 3% from 2021. The total fertility rate for Australian women stood at 1.63 births per woman. Hence, the ascending incidence of infertility is propelling the follicle-stimulating hormone market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12486&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Follicle Stimulating Hormone Market?
A significant trend emerging in the follicle-stimulating hormone market is that of product innovations. To establish their dominance in the market, prominent companies in the follicle-stimulating hormone sector are emphasizing on the development of innovative products. For example, in July 2024, Proov, a company based in the US that focuses on women's health, introduced the Proov Empower Perimenopause Testing System. This is a non-invasive, repeated urine test that measures four essential hormones - FSH, E1G which is an estrogen marker, PdG which is a progesterone marker, and LH - impacting symptoms and shaping the perimenopause journey. Proov Empower provides in-depth, tailored insights into the effect of a woman's hormone variations on her general health and wellness. By offering regular retesting, Proov Empower enables women to monitor hormonal changes and symptoms, functioning as a crucial aid during the menopause transition.

How Is the Follicle Stimulating Hormone Market Segmented?
The follicle stimulating hormone market covered in this report is segmented -

1) By Type: Recombinant FSH, Urinary FSH
2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications
3) By End-Users: Infertility Center, Hospitals, Other End-Users

Subsegments:
1) By Recombinant FSH: Pure Recombinant FSH, Mixed Recombinant FSH Formulations
2) By Urinary FSH: Purified Urinary FSH, Urinary FSH Combined With Other Hormones

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12486&type=smp

Which Companies Are Leading the Charge in Follicle Stimulating Hormone Market Innovation?
Major companies operating in the follicle stimulating hormone market include Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem's life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.

Which Regions Are Leading the Global Follicle Stimulating Hormone Market in Revenue?
North America was the largest region in the follicle stimulating hormone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12486

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.